Imaging of brain tumors: MR spectroscopy and metabolic imaging

Neuroimaging Clinics of North America

Volumn 20, Issue 3, 2010, Pages 293-310

  Horská, Alena ^a   Barker, Peter B ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KENNEDY KRIEGER INSTITUTE   (United States)

Author keywords

Brain tumors; Magnetic resonance spectroscopy; Metabolites; Spectroscopic imaging

Indexed keywords

CHOLINE; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ASTROCYTOMA; BRACHYTHERAPY; BRAIN ABSCESS; BRAIN ISCHEMIA; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; DEMYELINATING DISEASE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; GAMMA KNIFE RADIOSURGERY; GLIOBLASTOMA; GLIOMA; HUMAN; MEDICAL ASSESSMENT; MONITORING; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGODENDROGLIOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RADIATION INJURY; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING; TUMOR CLASSIFICATION;

BRAIN; BRAIN DISEASES; BRAIN NEOPLASMS; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; NEOPLASM INVASIVENESS; SURVIVAL ANALYSIS;

EID: 77955573546     PISSN: 10525149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nic.2010.04.003     Document Type: Review

References (113)

1. Bottomley P.A., Edelstein W.A., Foster T.H., et al. In vivo solvent-suppressed localized hydrogen nuclear magnetic resonance spectroscopy: a window to metabolism?. Proc Natl Acad Sci U S A 1985, 82(7):2148-2152.
2. Hanstock C.C., Rothman D.L., Prichard J.W., et al. Spatially localized 1H NMR spectra of metabolites in the human brain. Proc Natl Acad Sci U S A 1988, 85(6):1821-1825.
3. Frahm J., Bruhn H., Gyngell M.L., et al. Localized high-resolution proton NMR spectroscopy using stimulated echoes: initial applications to human brain in vivo. Magn Reson Med 1989, 9(1):79-93.
4. Bruhn H., Frahm J., Gyngell M.L., et al. Noninvasive differentiation of tumors with use of localized H-1 MR spectroscopy in vivo: initial experience in patients with cerebral tumors. Radiology 1989, 172(2):541-548.
5. Barker P.B., Glickson J.D., Bryan R.N. In vivo magnetic resonance spectroscopy of human brain tumors. Top Magn Reson Imaging 1993, 5(1):32-45.
6. Ouwerkerk R., Bleich K.B., Gillen J.S., et al. Tissue sodium concentration in human brain tumors as measured with 23Na MR imaging. Radiology 2003, 227(2):529-537.
7. Bottomley P.A. Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci 1987, 508:333-348.
8. Frahm J. Localized proton spectroscopy using stimulated echoes. J Magn Reson 1987, 72(3):502-508.
9. Brown T.R., Kincaid B.M., Ugurbil K. NMR chemical shift imaging in three dimensions. Proc Natl Acad Sci U S A 1982, 79(11):3523-3526.
10. Hourani R., Horska A., Albayram S., et al. Proton magnetic resonance spectroscopic imaging to differentiate between nonneoplastic lesions and brain tumors in children. J Magn Reson Imaging 2006, 23(2):99-107.
11. Langkowski J.H., Wieland J., Bomsdorf H., et al. Pre-operative localized in vivo proton spectroscopy in cerebral tumors at 4.0 Tesla-first results. Magn Reson Imaging 1989, 7(5):547-555.
12. Barker P.B. N-acetyl aspartate-a neuronal marker?. Ann Neurol 2001, 49(4):423-424.
13. Gupta R.K., Cloughesy T.F., Sinha U., et al. Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. J Neurooncol 2000, 50(3):215-226.
14. Croteau D., Scarpace L., Hearshen D., et al. Correlation between magnetic resonance spectroscopy imaging and image-guided biopsies: semiquantitative and qualitative histopathological analyses of patients with untreated glioma. Neurosurgery 2001, 49(4):823-829.
15. Herholz K., Heindel W., Luyten P.R., et al. In vivo imaging of glucose consumption and lactate concentration in human gliomas. Ann Neurol 1992, 31(3):319-327.
16. Castillo M., Smith J.K., Kwock L. Correlation of myo-inositol levels and grading of cerebral astrocytomas. AJNR Am J Neuroradiol 2000, 21(9):1645-1649.
17. Hattingen E., Raab P., Franz K., et al. Myo-inositol: a marker of reactive astrogliosis in glial tumors?. NMR Biomed 2008, 21(3):233-241.
18. Alger J.R., Frank J.A., Bizzi A., et al. Metabolism of human gliomas: assessment with H-1 MR spectroscopy and F-18 fluorodeoxyglucose PET. Radiology 1990, 177(3):633-641.
19. Howe F.A., Barton S.J., Cudlip S.A., et al. Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med 2003, 49(2):223-232.
20. Kuesel A.C., Sutherland G.R., Halliday W., et al. 1H MRS of high grade astrocytomas: mobile lipid accumulation in necrotic tissue. NMR Biomed 1994, 7(3):149-155.
21. Di Costanzo A., Scarabino T., Trojsi F., et al. Proton MR spectroscopy of cerebral gliomas at 3 T: spatial heterogeneity, and tumour grade and extent. Eur Radiol 2008, 18(8):1727-1735.
22. Saraf-Lavi E., Bowen B.C., Pattany P.M., et al. Proton MR spectroscopy of gliomatosis cerebri: case report of elevated myoinositol with normal choline levels. AJNR Am J Neuroradiol 2003, 24(5):946-951.
23. Arnold D.L., Shoubridge E.A., Villemure J.G., et al. Proton and phosphorus magnetic resonance spectroscopy of human astrocytomas in vivo. Preliminary observations on tumor grading. NMR Biomed 1990, 3(4):184-189.
24. Gill S.S., Thomas D.G., Van Bruggen N., et al. Proton MR spectroscopy of intracranial tumours: in vivo and in vitro studies. J Comput Assist Tomogr 1990, 14(4):497-504.
25. Preul M.C., Leblanc R., Caramanos Z., et al. Magnetic resonance spectroscopy guided brain tumor resection: differentiation between recurrent glioma and radiation change in two diagnostically difficult cases. Can J Neurol Sci 1998, 25(1):13-22.
26. Ricci P.E., Pitt A., Keller P.J., et al. Effect of voxel position on single-voxel MR spectroscopy findings. AJNR Am J Neuroradiol 2000, 21(2):367-374.
27. Senft C., Hattingen E., Pilatus U., et al. Diagnostic value of proton magnetic resonance spectroscopy in the noninvasive grading of solid gliomas: comparison of maximum and mean choline values. Neurosurgery 2009, 65(5):908-913. [discussion: 913].
28. Chawla S., Wang S., Wolf R.L., et al. Arterial spin-labeling and MR spectroscopy in the differentiation of gliomas. AJNR Am J Neuroradiol 2007, 28(9):1683-1689.
29. Preul M.C., Caramanos Z., Collins D.L., et al. Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat Med 1996, 2(3):323-325.
30. Tate A.R., Griffiths J.R., Martinez-Perez I., et al. Towards a method for automated classification of 1H MRS spectra from brain tumours. NMR Biomed 1998, 11(4-5):177-191.
31. De Edelenyi F.S., Rubin C., Esteve F., et al. A new approach for analyzing proton magnetic resonance spectroscopic images of brain tumors: nosologic images. Nat Med 2000, 6(11):1287-1289.
32. Tate A.R., Majos C., Moreno A., et al. Automated classification of short echo time in in vivo 1H brain tumor spectra: a multicenter study. Magn Reson Med 2003, 49(1):29-36.
33. Demir M.K., Iplikcioglu A.C., Dincer A., et al. Single voxel proton MR spectroscopy findings of typical and atypical intracranial meningiomas. Eur J Radiol 2006, 60(1):48-55.
34. Fan G., Sun B., Wu Z., et al. In vivo single-voxel proton MR spectroscopy in the differentiation of high-grade gliomas and solitary metastases. Clin Radiol 2004, 59(1):77-85.
35. Chiang I.C., Kuo Y.T., Lu C.Y., et al. Distinction between high-grade gliomas and solitary metastases using peritumoral 3-T magnetic resonance spectroscopy, diffusion, and perfusion imagings. Neuroradiology 2004, 46(8):619-627.
36. Ishimaru H., Morikawa M., Iwanaga S., et al. Differentiation between high-grade glioma and metastatic brain tumor using single-voxel proton MR spectroscopy. Eur Radiol 2001, 11(9):1784-1791.
37. Omuro A.M., Leite C.C., Mokhtari K., et al. Pitfalls in the diagnosis of brain tumours. Lancet Neurol 2006, 5(11):937-948.
38. Hourani R., Brant L.J., Rizk T., et al. Can proton MR spectroscopic and perfusion imaging differentiate between neoplastic and nonneoplastic brain lesions in adults?. AJNR Am J Neuroradiol 2008, 29(2):366-372.
39. Saindane A.M., Cha S., Law M., et al. Proton MR spectroscopy of tumefactive demyelinating lesions. AJNR Am J Neuroradiol 2002, 23(8):1378-1386.
40. Butzen J., Prost R., Chetty V., et al. Discrimination between neoplastic and nonneoplastic brain lesions by use of proton MR spectroscopy: the limits of accuracy with a logistic regression model. AJNR Am J Neuroradiol 2000, 21(7):1213-1219.
41. Moller-Hartmann W., Herminghaus S., Krings T., et al. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 2002, 44(5):371-381.
42. Poptani H., Gupta R.K., Roy R., et al. Characterization of intracranial mass lesions with in vivo proton MR spectroscopy. AJNR Am J Neuroradiol 1995, 16(8):1593-1603.
43. Poptani H., Kaartinen J., Gupta R.K., et al. Diagnostic assessment of brain tumours and non-neoplastic brain disorders in vivo using proton nuclear magnetic resonance spectroscopy and artificial neural networks. J Cancer Res Clin Oncol 1999, 125(6):343-349.
44. Rand S.D., Prost R., Haughton V., et al. Accuracy of single-voxel proton MR spectroscopy in distinguishing neoplastic from nonneoplastic brain lesions. AJNR Am J Neuroradiol 1997, 18(9):1695-1704.
45. De Stefano N., Caramanos Z., Preul M.C., et al. In vivo differentiation of astrocytic brain tumors and isolated demyelinating lesions of the type seen in multiple sclerosis using 1H magnetic resonance spectroscopic imaging. Ann Neurol 1998, 44(2):273-278.
46. Venkatesh S.K., Gupta R.K., Pal L., et al. Spectroscopic increase in choline signal is a nonspecific marker for differentiation of infective/inflammatory from neoplastic lesions of the brain. J Magn Reson Imaging 2001, 14(1):8-15.
47. Vuori K., Kankaanranta L., Hakkinen A.M., et al. Low-grade gliomas and focal cortical developmental malformations: differentiation with proton MR spectroscopy. Radiology 2004, 230(3):703-708.
48. Majos C., Aguilera C., Alonso J., et al. Proton MR spectroscopy improves discrimination between tumor and pseudotumoral lesion in solid brain masses. AJNR Am J Neuroradiol 2009, 30(3):544-551.
49. Al-Okaili R.N., Krejza J., Wang S., et al. Advanced MR imaging techniques in the diagnosis of intraaxial brain tumors in adults. Radiographics 2006, 26(Suppl 1):S173-S189.
50. Al-Okaili R.N., Krejza J., Woo J.H., et al. Intraaxial brain masses: MR imaging-based diagnostic strategy-initial experience. Radiology 2007, 243(2):539-550.
51. Law M., Hamburger M., Johnson G., et al. Differentiating surgical from non-surgical lesions using perfusion MR imaging and proton MR spectroscopic imaging. Technol Cancer Res Treat 2004, 3(6):557-565.
52. Remy C., Grand S., Lai E.S., et al. 1H MRS of human brain abscesses in vivo and in vitro. Magn Reson Med 1995, 34(4):508-514.
53. Garg M., Gupta R.K. MR Spectroscopy in intracranial infection. Clinical MR neuroimaging: diffusion, perfusion and spectroscopy 2004, 380-406. Cambridge University Press, Cambridge (UK). J.H. Gillard, A.D. Waldman, P.B. Barker (Eds.).
54. Desprechins B., Stadnik T., Koerts G., et al. Use of diffusion-weighted MR imaging in differential diagnosis between intracerebral necrotic tumors and cerebral abscesses. AJNR Am J Neuroradiol 1999, 20(7):1252-1257.
55. Saraswathy S., Crawford F.W., Lamborn K.R., et al. Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy. J Neurooncol 2009, 91(1):69-81.
56. Crawford F.W., Khayal I.S., McGue C., et al. Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM. J Neurooncol 2009, 91(3):337-351.
57. Arslanoglu A., Bonekamp D., Barker P.B., et al. Quantitative proton MR spectroscopic imaging of the mesial temporal lobe. J Magn Reson Imaging 2004, 20(5):772-778.
58. Chan A.A., Lau A., Pirzkall A., et al. Proton magnetic resonance spectroscopy imaging in the evaluation of patients undergoing gamma knife surgery for Grade IV glioma. J Neurosurg 2004, 101(3):467-475.
59. Guzman-de-Villoria J.A., Sanchez-Gonzalez J., Munoz L., et al. 1H MR spectroscopy in the assessment of gliomatosis cerebri. AJR Am J Roentgenol 2007, 188(3):710-714.
60. Alexander A., Murtha A., Abdulkarim B., et al. Prognostic significance of serial magnetic resonance spectroscopies over the course of radiation therapy for patients with malignant glioma. Clin Invest Med 2006, 29(5):301-311.
61. Kuznetsov Y.E., Caramanos Z., Antel S.B., et al. Proton magnetic resonance spectroscopic imaging can predict length of survival in patients with supratentorial gliomas. Neurosurgery 2003, 53(3):565-574. [discussion: 574-6].
62. Sjobakk T.E., Johansen R., Bathen T.F., et al. Metabolic profiling of human brain metastases using in vivo proton MR spectroscopy at 3T. BMC Cancer 2007, 7:141.
63. Raizer J.J., Koutcher J.A., Abrey L.E., et al. Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma. J Neurooncol 2005, 71(2):173-180.
64. Hattingen E., Raab P., Franz K., et al. Prognostic value of choline and creatine in WHO grade II gliomas. Neuroradiology 2008, 50(9):759-767.
65. Marcus K.J., Astrakas L.G., Zurakowski D., et al. Predicting survival of children with CNS tumors using proton magnetic resonance spectroscopic imaging biomarkers. Int J Oncol 2007, 30(3):651-657.
66. Warren K.E., Frank J.A., Black J.L., et al. Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors. J Clin Oncol 2000, 18(5):1020-1026.
67. Hermann E.J., Hattingen E., Krauss J.K., et al. Stereotactic biopsy in gliomas guided by 3-tesla 1H-chemical-shift imaging of choline. Stereotact Funct Neurosurg 2008, 86(5):300-307.
68. Di Costanzo A., Scarabino T., Trojsi F., et al. Multiparametric 3T MR approach to the assessment of cerebral gliomas: tumor extent and malignancy. Neuroradiology 2006, 48(9):622-631.
69. Chang S.M., Nelson S., Vandenberg S., et al. Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma. J Neurooncol 2009, 92(3):401-415.
70. Weber M.A., Giesel F.L., Stieltjes B. MRI for identification of progression in brain tumors: from morphology to function. Expert Rev Neurother 2008, 8(10):1507-1525.
71. Martin A.J., Liu H., Hall W.A., et al. Preliminary assessment of turbo spectroscopic imaging for targeting in brain biopsy. AJNR Am J Neuroradiol 2001, 22(5):959-968.
72. Klingebiel R., Bohner G. Neuroimaging. Recent Results Cancer Res 2009, 171:175-190.
73. Dowling C., Bollen A.W., Noworolski S.M., et al. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. AJNR Am J Neuroradiol 2001, 22(4):604-612.
74. Hall W.A., Martin A., Liu H., et al. Improving diagnostic yield in brain biopsy: coupling spectroscopic targeting with real-time needle placement. J Magn Reson Imaging 2001, 13(1):12-15.
75. Hall W.A., Galicich W., Bergman T., et al. 3-Tesla intraoperative MR imaging for neurosurgery. J Neurooncol 2006, 77(3):297-303.
76. Ganslandt O., Stadlbauer A., Fahlbusch R., et al. Proton magnetic resonance spectroscopic imaging integrated into image-guided surgery: correlation to standard magnetic resonance imaging and tumor cell density. Neurosurgery 2005, 56(Suppl 2):291-298. [discussion: 291-8].
77. Stadlbauer A., Nimsky C., Buslei R., et al. Proton magnetic resonance spectroscopic imaging in the border zone of gliomas: correlation of metabolic and histological changes at low tumor infiltration-initial results. Invest Radiol 2007, 42(4):218-223.
78. Lee M.C., Nelson S.J. Supervised pattern recognition for the prediction of contrast-enhancement appearance in brain tumors from multivariate magnetic resonance imaging and spectroscopy. Artif Intell Med 2008, 43(1):61-74.
79. Menze B.H., Kelm B.M., Weber M.A., et al. Mimicking the human expert: pattern recognition for an automated assessment of data quality in MR spectroscopic images. Magn Reson Med 2008, 59(6):1457-1466.
80. Wright A.J., Fellows G., Byrnes T.J., et al. Pattern recognition of MRSI data shows regions of glioma growth that agree with DTI markers of brain tumor infiltration. Magn Reson Med 2009, 62(6):1646-1651.
81. Robertson P.L. Advances in treatment of pediatric brain tumors. NeuroRx 2006, 3(2):276-291.
82. Combs S.E. Radiation therapy. Recent Results Cancer Res 2009, 171:125-140.
83. Pirzkall A., McKnight T.R., Graves E.E., et al. MR-spectroscopy guided target delineation for high-grade gliomas. Int J Radiat Oncol Biol Phys 2001, 50(4):915-928.
84. Nelson S.J., Graves E., Pirzkall A., et al. In vivo molecular imaging for planning radiation therapy of gliomas: an application of 1H MRSI. J Magn Reson Imaging 2002, 16(4):464-476.
85. Payne G.S., Leach M.O. Applications of magnetic resonance spectroscopy in radiotherapy treatment planning. Br J Radiol 2006, 79(Spec No 1):S16-S26.
86. McKnight T.R., von dem Bussche M.H., Vigneron D.B., et al. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg 2002, 97(4):794-802.
87. Yang I., Aghi M.K. New advances that enable identification of glioblastoma recurrence. Nat Rev Clin Oncol 2009, 6(11):648-657.
88. Sundgren P.C. MR spectroscopy in radiation injury. AJNR Am J Neuroradiol 2009, 30(8):1469-1476.
89. Taylor J.S., Langston J.W., Reddick W.E., et al. Clinical value of proton magnetic resonance spectroscopy for differentiating recurrent or residual brain tumor from delayed cerebral necrosis. Int J Radiat Oncol Biol Phys 1996, 36(5):1251-1261.
90. Wald L.L., Nelson S.J., Day M.R., et al. Serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy. J Neurosurg 1997, 87(4):525-534.
91. Chernov M.F., Hayashi M., Izawa M., et al. Multivoxel proton MRS for differentiation of radiation-induced necrosis and tumor recurrence after gamma knife radiosurgery for brain metastases. Brain Tumor Pathol 2006, 23(1):19-27.
92. Rock J.P., Hearshen D., Scarpace L., et al. Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis. Neurosurgery 2002, 51(4):912-919. [discussion: 919-20].
93. Law M. MR spectroscopy of brain tumors. Top Magn Reson Imaging 2004, 15(5):291-313.
94. Li X., Vigneron D.B., Cha S., et al. Relationship of MR-derived lactate, mobile lipids, and relative blood volume for gliomas in vivo. AJNR Am J Neuroradiol 2005, 26(4):760-769.
95. Smith E.A., Carlos R.C., Junck L.R., et al. Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions. AJR Am J Roentgenol 2009, 192(2):W45-W52.
96. Rock J.P., Scarpace L., Hearshen D., et al. Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis. Neurosurgery 2004, 54(5):1111-1117. [discussion: 1117-9].
97. Zeng Q.S., Li C.F., Liu H., et al. Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging. Int J Radiat Oncol Biol Phys 2007, 68(1):151-158.
98. Graves E.E., Nelson S.J., Vigneron D.B., et al. Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery. AJNR Am J Neuroradiol 2001, 22(4):613-624.
99. Lichy M.P., Plathow C., Schulz-Ertner D., et al. Follow-up gliomas after radiotherapy: 1H MR spectroscopic imaging for increasing diagnostic accuracy. Neuroradiology 2005, 47(11):826-834.
100. Heesters M.A., Kamman R.L., Mooyaart E.L., et al. Localized proton spectroscopy of inoperable brain gliomas. Response to radiation therapy. J Neurooncol 1993, 17(1):27-35.
101. Tedeschi G., Lundbom N., Raman R., et al. Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. J Neurosurg 1997, 87(4):516-524.
102. Laprie A., Catalaa I., Cassol E., et al. Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study. Int J Radiat Oncol Biol Phys 2008, 70(3):773-781.
103. Sundgren P.C., Nagesh V., Elias A., et al. Metabolic alterations: a biomarker for radiation-induced normal brain injury-an MR spectroscopy study. J Magn Reson Imaging 2009, 29(2):291-297.
104. Esteve F., Rubin C., Grand S., et al. Transient metabolic changes observed with proton MR spectroscopy in normal human brain after radiation therapy. Int J Radiat Oncol Biol Phys 1998, 40(2):279-286.
105. Wick W., Weller M. Adjuvant therapy. Gliomas, recent results in cancer research 2009, 141-153. Springer-Verlag, Heidelberg (Germany). A.V. Deimling (Ed.).
106. Schwarz A.J., Maisey N.R., Collins D.J., et al. Early in vivo detection of metabolic response: a pilot study of 1H MR spectroscopy in extracranial lymphoma and germ cell tumours. Br J Radiol 2002, 75(900):959-966.
107. Preul M.C., Caramanos Z., Villemure J.G., et al. Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy. Neurosurgery 2000, 46(2):306-318.
108. Balmaceda C., Critchell D., Mao X., et al. Multisection 1H magnetic resonance spectroscopic imaging assessment of glioma response to chemotherapy. J Neurooncol 2006, 76(2):185-191.
109. Murphy P.S., Viviers L., Abson C., et al. Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy. Br J Cancer 2004, 90(4):781-786.
110. Lichy M.P., Bachert P., Henze M., et al. Monitoring individual response to brain-tumour chemotherapy: proton MR spectroscopy in a patient with recurrent glioma after stereotactic radiotherapy. Neuroradiology 2004, 46(2):126-129.
111. Dyke J.P., Sanelli P.C., Voss H.U., et al. Monitoring the effects of BCNU chemotherapy Wafers (Gliadel) in glioblastoma multiforme with proton magnetic resonance spectroscopic imaging at 3.0 Tesla. J Neurooncol 2007, 82(1):103-110.
112. Golay X., Gillen J., van Zijl P.C., et al. Scan time reduction in proton magnetic resonance spectroscopic imaging of the human brain. Magn Reson Med 2002, 47(2):384-387.
113. Heerschap A. In vivo magnetic resonance spectroscopy in clinical oncology. Cancer drug discovery and development: in vivo imaging of cancer therapy 2007, 241-258. Humana Press Inc, Totowa (NJ). A. Shields, P. Price (Eds.).